Meeting
2013 ASCO Annual Meeting
Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma patients.
Authors
Miguel F. Sanmamed
Department of Oncology, University of Navarra, Pamplona, Spain
Miguel F. Sanmamed , Sara Fernandez-Landazuri , Eduardo Castanon , Jose Echeveste , Maria D. Lozano , Miguel A. Idoate , Jose Luis Perez-Gracia , Alvaro Gonzalez , Salvador Martin-Algarra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9074)
DOI
10.1200/jco.2013.31.15_suppl.9074
Abstract #
9074
Poster Bd #
48E
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A powerful drug combination strategy targeting BRAF-mutant melanoma.
First Author: Luke Daniel Rothermel
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2016 ASCO Annual Meeting
Real-world overall survival in advanced melanoma from the IMAGE study.
First Author: Mark R. Middleton
Poster
2014 ASCO Annual Meeting
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.
First Author: Friedegund Elke Meier